Yamada H, Omata-Yamada T, Lengyel P
Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06511.
J Biol Chem. 1991 Feb 25;266(6):4002-9.
We have reported earlier the isolation of two recessive, serum- and anchorage-dependent revertants from an NIH 3T3 line which had been transformed with multiple copies of a c-H-ras oncogene. In both revertants the oncogene was fully expressed and fusion of either revertant with normal (untransformed) cells or of the two revertants with one another resulted in transformed progeny. These, and other data indicate that the transforming activity of the c-H-ras oncogene is impaired in the two revertants, in consequence of defects in distinct genes needed to mediate this activity. Here, we describe some of the biochemical features of the revertants. In both of these (as in the transformed line) the bulk of the ras-p21 protein was found in the membrane fraction. This suggests proper posttranslational processing. Furthermore, no difference was detected either in the ras-p21 protein GTPase stimulating activity of GAP or in the extent of GAP-tyrosine phosphorylation among growing cultures of the two revertants, the transformed line and the parental NIH 3T3 line. The level of glucose transporter mRNA was severalfold higher in the transformed line than in the NIH 3T3 line. In the two revertants, however, the level was as low as that in the NIH 3T3 line. This indicates that the reversion impaired the effect of the c-H-ras oncogene on transcription. The raf oncogene (proposed to increase transcription factor activity) could retransform both revertants. Moreover, as revealed in experiments with growing cultures, neither transformation by the c-H-ras oncogene nor reversion from the transformed state altered the electrophoretic mobility of the raf protein or the level of its actin kinase activity. These results suggest that transformation by the c-H-ras oncogene is not mediated by the activation of raf protein kinase. The tyrosine phosphorylation of the p34cdc2 protein kinase (a cell cycle regulatory enzyme) was severalfold higher in the transformed line than in the NIH 3T3 line. The level of p34cdc2 protein kinase phosphorylation was as high in the R260 revertant as in the transformed line and as low in the R116 revertant as in the NIH 3T3 line. We are attempting to identify the defective mediator genes impairing the transforming activity of the c-H-ras oncogene in the two revertants.
我们之前报道过,从一个用多个c-H-ras癌基因拷贝转化的NIH 3T3细胞系中分离出了两个隐性的、依赖血清和贴壁的回复突变体。在这两个回复突变体中,癌基因均充分表达,且任一回复突变体与正常(未转化)细胞融合,或两个回复突变体相互融合,都会产生转化后代。这些以及其他数据表明,在这两个回复突变体中,c-H-ras癌基因的转化活性受损,这是由于介导该活性所需的不同基因存在缺陷。在此,我们描述这些回复突变体的一些生化特征。在这两个回复突变体中(如同在转化细胞系中一样),大部分ras-p21蛋白存在于膜组分中。这表明存在适当的翻译后加工。此外,在两个回复突变体、转化细胞系和亲本NIH 3T3细胞系的生长培养物中,未检测到GAP对ras-p21蛋白GTP酶刺激活性的差异,也未检测到GAP酪氨酸磷酸化程度的差异。转化细胞系中葡萄糖转运体mRNA水平比NIH 3T3细胞系高几倍。然而,在两个回复突变体中,该水平与NIH 3T3细胞系一样低。这表明回复突变损害了c-H-ras癌基因对转录的影响。raf癌基因(推测可增加转录因子活性)可使两个回复突变体再次发生转化。此外,从生长培养物实验中可以看出,c-H-ras癌基因介导的转化或从转化状态的回复均未改变raf蛋白的电泳迁移率或其肌动蛋白激酶活性水平。这些结果表明,c-H-ras癌基因介导的转化不是由raf蛋白激酶的激活介导的。p34cdc2蛋白激酶(一种细胞周期调节酶)的酪氨酸磷酸化在转化细胞系中比在NIH 3T3细胞系中高几倍。在R260回复突变体中,p-蛋白激酶磷酸化水平与转化细胞系中一样高,而在R116回复突变体中与NIH 3T3细胞系中一样低。我们正在尝试鉴定在这两个回复突变体中损害c-H-ras癌基因转化活性的缺陷介导基因。